| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (replaced TA175, terminated appraisal) |
|
Medicine details |
|
| Medicine name | gefitinib (Iressa®) |
| Formulation | 250 mg film coated tablet |
| Reference number | 337 |
| Indication | Treatment of adults with locally advanced or metastatic non small cell lung cancer eligible for further chemotherapy after receiving prior platinum based chemotherapy |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 23/10/2008 |
| NICE guidance | |